Transcriptomic analysis identifies differences in gene expression in actinic keratoses after treatment with imiquimod and between responders and non responders
Megan H. Trager, Emanuelle M. Rizk, Sharon Rose et al. · Scientific Reports · 2021
The presence of actinic keratoses (AKs) increases a patient's risk of developing squamous cell carcinoma by greater than six-fold. We evaluated the effect of topical treatment with imiquimod on the tumor microenvironment by measuring transcriptomic differences in AKs before and after treatment with imiquimod 3.75%. Biopsies were collected prospectively from 21 patients and examined histologically. RNA was extracted and transcriptomic analyses of 788 genes were performed using the nanoString assay. Imiquimod decreased number of AKs by study endpoint at week 14 (p < 0.0001). Post-imiquimod therapy, levels of CDK1, CXCL13, IL1B, GADPH, TTK, ILF3, EWSR1, BIRC5, PLAUR, ISG20, and C1QBP were significantly lower (adjusted p < 0.05). Complete responders (CR) exhibited a distinct pattern of inflammatory gene expression pre-treatment relative to incomplete responders (IR), with alterations in 15 inflammatory pathways (p < 0.05) reflecting differential expression of 103 genes (p < 0.05). Presence of adverse effects was associated with improved treatment response. Differences in gene expression were found between pre-treatment samples in CR versus IR, suggesting that higher levels of inflammation pre-treament may play a part in regression of AKs. Further characterization of the immune micro-environment in AKs may help develop biomarkers predictive of response to topical immune modulators and may guide therapy.
Cited by 2 works. doi:10.1038/s41598-021-88424-z Open-access PDF
Authors
- Megan H. Trager
- Emanuelle M. Rizk
- Sharon Rose
- Kuixi Zhu
- Branden Lau
- Benjamin T. Fullerton
- Jaya Sarin Pradhan
- Ayush Srivastava
- Giselle Singer
- Robyn D. Gartrell
- Rui R. Chang
- Larisa J. Geskin
- Yvonne M. Saenger
- Gary Goldenberg
References
- Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway
- The burden of skin diseases: 2004
- Cytokine induction in mice by the immunomodulator imiquimod
- Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod
- Actinic keratoses
- S100 proteins in cancer
- A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up
- variancePartition: interpreting drivers of variation in complex gene expression studies
- Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: Results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles
- Current perspective on actinic keratosis: a review